Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05985863
PHASE1/PHASE2

Human Umbilical Cord Mesenchymal Stem Cell Transplantation for The Treatment of Acute-on-Chronic Liver Failure

Sponsor: Beijing 302 Hospital

View on ClinicalTrials.gov

Summary

This study is a randomized double-blind placebo-controlled multicenter clinical trial to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell (UC-MSC) transplantation for the treatment of acute-on-chronic liver failure (ACLF). UC-MSC therapy may improve the clinical outcomes of patients with ACLF. The trial would provide scientific evidence for UC-MSC transplantation as a potential treatment for ACLF.

Official title: Clinical Research of Human Umbilical Cord Mesenchymal Stem Cell Transplantation for The Treatment of Acute-on-Chronic Liver Failure

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2023-09-30

Completion Date

2028-12-30

Last Updated

2024-05-07

Healthy Volunteers

No

Interventions

DRUG

standard medical treatment

standard medical treatment for ACLF

DRUG

Placebo

5% human serum albumin in 0.9% saline (at week0, week1 and week2)

DRUG

hUC-MSC

hUC-MSC (1.5×10\^8 cells/time, Peripheral IV, at week0, week1 and week2)

DRUG

hUC-MSC_Prolonged

hUC-MSC (1.5×10\^8 cells/time, Peripheral IV, at week4 and week5)

Locations (1)

the Fifth Medical Center, Chinese PLA General Hospital

Beijing, Beijing Municipality, China